Literature DB >> 24986089

Medical therapy of gliomas.

Manmeet S Ahluwalia1, Susan M Chang.   

Abstract

Medical therapies are an important part of adjunctive therapy for gliomas. In this chapter we will review the chemotherapeutic and targeted agents that have been evaluated in clinical trials in grade II-IV gliomas in the last decade. A number of randomized phase III trials were completed and reported. There has been a clear success in oligodendroglial tumors and low grade glioma. Although some progress has been made in glioblastoma, considerable work involving the multidisciplinary collaboration of basic science, translational and clinical investigators needs to be done to improve the outcome of patients with anaplastic astrocytoma and glioblastoma. In addition, tailoring treatment based on molecular cytogenetic characteristics is a major focus of research into precision based medicine for glioma.

Entities:  

Mesh:

Year:  2014        PMID: 24986089      PMCID: PMC4170021          DOI: 10.1007/s11060-014-1495-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  93 in total

1.  Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.

Authors:  Michael D Prados; Susan M Chang; Nicholas Butowski; Rebecca DeBoer; Rupa Parvataneni; Hannah Carliner; Paul Kabuubi; Jennifer Ayers-Ringler; Jane Rabbitt; Margaretta Page; Anne Fedoroff; Penny K Sneed; Mitchel S Berger; Michael W McDermott; Andrew T Parsa; Scott Vandenberg; C David James; Kathleen R Lamborn; David Stokoe; Daphne A Haas-Kogan
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

2.  Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.

Authors:  Marc C Chamberlain; Sandra Johnston
Journal:  J Neurooncol       Date:  2008-10-25       Impact factor: 4.130

3.  Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

Authors:  Paul D Brown; Sunil Krishnan; Jann N Sarkaria; Wenting Wu; Kurt A Jaeckle; Joon H Uhm; Francois J Geoffroy; Robert Arusell; Gaspar Kitange; Robert B Jenkins; John W Kugler; Roscoe F Morton; Kendrith M Rowland; Paul Mischel; William H Yong; Bernd W Scheithauer; David Schiff; Caterina Giannini; Jan C Buckner
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

4.  Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.

Authors:  David A Reardon; Karen L Fink; Tom Mikkelsen; Timothy F Cloughesy; Alison O'Neill; Scott Plotkin; Michael Glantz; Paula Ravin; Jeffrey J Raizer; Keith M Rich; David Schiff; William R Shapiro; Susan Burdette-Radoux; Edward J Dropcho; Sabine M Wittemer; Johannes Nippgen; Martin Picard; L Burt Nabors
Journal:  J Clin Oncol       Date:  2008-11-03       Impact factor: 44.544

5.  Analysis of the IDH1 codon 132 mutation in brain tumors.

Authors:  Jörg Balss; Jochen Meyer; Wolf Mueller; Andrey Korshunov; Christian Hartmann; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2008-11-05       Impact factor: 17.088

Review 6.  The potential role and application of PARP inhibitors in cancer treatment.

Authors:  Anthony J Chalmers
Journal:  Br Med Bull       Date:  2009-02-09       Impact factor: 4.291

7.  Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

Authors:  Martin J van den Bent; Alba A Brandes; Roy Rampling; Mathilde C M Kouwenhoven; Johan M Kros; Antoine F Carpentier; Paul M Clement; Marc Frenay; Mario Campone; Jean-Francois Baurain; Jean-Paul Armand; Martin J B Taphoorn; Alicia Tosoni; Heidemarie Kletzl; Barbara Klughammer; Denis Lacombe; Thierry Gorlia
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

8.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Authors:  Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

9.  Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.

Authors:  Michael A Vogelbaum; Brian Berkey; David Peereboom; David Macdonald; Caterina Giannini; John H Suh; Robert Jenkins; James Herman; Paul Brown; Deborah T Blumenthal; Christopher Biggs; Christopher Schultz; Minesh Mehta
Journal:  Neuro Oncol       Date:  2008-09-08       Impact factor: 12.300

10.  IDH1 and IDH2 mutations in gliomas.

Authors:  Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 176.079

View more
  10 in total

1.  Current Management of Adult Diffuse Infiltrative Low Grade Gliomas.

Authors:  Emilie Le Rhun; Sophie Taillibert; Marc C Chamberlain
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 5.081

2.  miR-373 Inhibits Glioma Cell U251 Migration and Invasion by Down-Regulating CD44 and TGFBR2.

Authors:  Furong Wei; Qianrong Wang; Qinghong Su; Haiyan Huang; Junwen Luan; Xiaoqun Xu; Junfu Wang
Journal:  Cell Mol Neurobiol       Date:  2016-02-08       Impact factor: 5.046

3.  GATA2 promotes glioma progression through EGFR/ERK/Elk-1 pathway.

Authors:  Zhongyong Wang; Hui Yuan; Chao Sun; Liang Xu; Yanming Chen; Qing Zhu; Haifeng Zhao; Qiang Huang; Jun Dong; Qing Lan
Journal:  Med Oncol       Date:  2015-02-24       Impact factor: 3.064

4.  Long non-coding RNA LINC01018 inhibits human glioma cell proliferation and metastasis by directly targeting miRNA-182-5p.

Authors:  Hu Su; Zhao Hailin; Luo Dongdong; Yin Jiang; Huang Shuncheng; Zhang Shun; Li Dan; Peng Biao
Journal:  J Neurooncol       Date:  2022-09-12       Impact factor: 4.506

Review 5.  Circulating biomarkers for gliomas.

Authors:  Manfred Westphal; Katrin Lamszus
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

6.  Ethanol Extract of Lycopodium serratum Thunb. Attenuates Lipopolysaccharide-Induced C6 Glioma Cells Migration via Matrix Metalloproteinase-9 Expression.

Authors:  Ju-Yeon Park; Hyuck Kim; Dong-Woo Lim; Jai-Eun Kim; Won-Hwan Park; Sun-Dong Park
Journal:  Chin J Integr Med       Date:  2018-01-15       Impact factor: 1.978

7.  Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma.

Authors:  Hiroshi Nakashima; Johanna K Kaufmann; Pin-Yi Wang; Tran Nguyen; Maria-Carmela Speranza; Kazue Kasai; Kazuo Okemoto; Akihiro Otsuki; Ichiro Nakano; Soledad Fernandez; William F Goins; Paola Grandi; Joseph C Glorioso; Sean Lawler; Timothy P Cripe; E Antonio Chiocca
Journal:  J Clin Invest       Date:  2015-10-20       Impact factor: 14.808

8.  Combination Therapy with Low Copper Diet, Penicillamine and Gamma Knife Radiosurgery Reduces VEGF and IL-8 In Patients with Recurrent Glioblastoma

Authors:  Alireza Feli; Shima Jazayeri; Mohammad Ali Bitaraf; Masoud Solaymani Dodaran; Karim Parastouei; Mohammad Javad Hosseinzadeh-Attar
Journal:  Asian Pac J Cancer Prev       Date:  2017-07-27

9.  Effects of Anticancer Agent P-bi-TAT on Gene Expression Link the Integrin Thyroid Hormone Receptor to Expression of Stemness and Energy Metabolism Genes in Cancer Cells.

Authors:  Gennadi V Glinsky; Kavitha Godugu; Thangirala Sudha; Mehdi Rajabi; Sridar V Chittur; Aleck A Hercbergs; Shaker A Mousa; Paul J Davis
Journal:  Metabolites       Date:  2022-04-04

10.  Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma.

Authors:  N-s Lai; D-g Wu; X-g Fang; Y-c Lin; S-s Chen; Z-b Li; S-s Xu
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.